Document is current
Any future updates will be listed below
-
Authors
Boguniewicz, Mark https://orcid.org/0000-0002-1015-4439
Sher, Lawrence D.
Paller, Amy S.
Arkwright, Peter D.
Yoshihara, Shigemi
Chen, Zhen
Shah, Parul
Marco, Ainara Rodríguez
-
Funding
Funding for this research was provided by:
Sanofi
Regeneron Pharmaceuticals
- License Information
-
More Information
Article History
Received: 4 February 2024
Accepted: 12 September 2024
First Online: 29 October 2024
Declarations
:
: Mark Boguniewicz has been an investigator for Incyte, Regeneron Pharmaceuticals Inc., and Sanofi, and participated on advisory boards for AbbVie, Amgen, Dermavant, Eli Lilly, Incyte, LEO Pharma, Pfizer, Regeneron Pharmaceuticals Inc., and Sanofi. Lawrence D. Sher is an advisory board member for Aimmune Therapeutics, Optinose, Regeneron Pharmaceuticals Inc., and Sanofi; reports speaker fees from Regeneron Pharmaceuticals Inc. and Sanofi; and clinical trials funding from Aimmune Therapeutics, Amgen, AstraZeneca, Circassia, DBV Technologies, Galderma, GSK, Lupin, Merck, Mylan, Novartis, Novo Nordisk, Optinose, Pearl, Pfizer, Pulmagen, Roxane, Sanofi, Spirometrix, Teva, Vectura, and Watson Pharmaceuticals. Amy S. Paller is an investigator for AbbVie, Dermavant, Eli Lilly, Incyte, Janssen, Krystal Biotech, LEO Pharma and UCB; a consultant for Amryt Pharma, Azitra, BioCryst, BMS, Boehringer Ingelheim, Castle Creek Biosciences, Eli Lilly, Janssen, Krystal Biotech, LEO Pharma, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, Seanergy, TWi Biotechnology, and UCB; and a member of the data and safety monitoring board for AbbVie, Abeona Therapeutics, Catawba Research, Galderma, and InMed Pharmaceuticals. Peter D. Arkwright has acted as an investigator for Regeneron Pharmaceuticals Inc., and has received grants from and acted as an advisor for Sanofi. Shigemi Yoshihara has acted as an investigator for Regeneron Pharmaceuticals Inc., and has received grants from and acted as an advisor for Sanofi. Zhen Chen and Parul Shah are employees and shareholders of Regeneron Pharmaceuticals Inc. Ainara Rodríguez Marco is an employee of and may hold stock and/or stock options in Sanofi.
: The LIBERTY AD PRESCHOOL part B study was conducted in accordance with the provisions of the Declaration of Helsinki, the International Council for Harmonisation Good Clinical Practice guidelines, and applicable regulatory requirements. The study protocol was reviewed and approved by institutional review boards/ethics committees. For each patient, written informed consent was obtained from a parent or legal guardian.
